Present in almost 60 countries worldwide, Egis Group’s net sales achieved EUR 510 million in its 2016/2017 business year, while sales value in the company’s key markets – Russia  and CIS countries – amounted at 161 million euros. The current transaction is another successful element of the company’s strategic objective aiming to strengthen competitiveness by acquisitions in key countries.

Newly acquired Sinuforte nasal spray is an OTC drug manufactured in the EU with the highest quality standards, its efficacy and safety are proven with clinical trials. The premium branded product has meaningful size in Russia and in the CIS countries, and is expected to be a leading product of the Egis portfolio in Russia.  As per the agreement, Egis receives all rights related to the product from Hartington Business S.L., including the rights to commercialise Sinuforte in Russia and CIS countries, as well as the patent related to the production method of the API and the finished product.

Sinuforte has strong fit with Egis’ current portfolio and operations, supported by Egis’ traditionally trusted relations with local professionals. Egis expects the substantial growth of Sinuforte by increasing the awareness of the disease and the product’s characteristics among healthcare professionals and patients, contributing to successful therapies, satisfying an unmet medical need that affects a large patient population. Egis is already distributing Sinuforte in Russia since October 2017.

The acquisition of Sinuforte entirely complies with our existing portfolio as well as with our ambitions and strategic objectives towards Russia. We continue to trace new possibilities to boost further growth in the region – stated in Egis-Russia.

Prior to the current transaction, in February 2017 Egis acquired Russian D-Panthenol and women’s health product portfolio from Jadran-Galenski Laboratorij (JGL).